Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2000

View Archived Issues

Phase II/III data, including subgroup analyses, on LJP-394 discussed at ACR meeting

Company Profile: BioMarin

Caspase inhibition offers new strategy for cardiomyopathy therapy

Company Profile: Tamarkin

Schering AG and Population Council establish MENT collaboration

Suntory and Chugai to codevelop rhPTH(1-34) for osteoporosis

Sildenafil tested in patients with LVD

Niaspan proves safe and effective in diabetics

Adenosine A1 and A3 receptor agonists protect the heart against ischemia

Novel strategy for selective myoblast proliferation explored

MS-325-enhanced MRI images visualize vessel wall inflammation and plaque burden

Epix Medical reports direct clot detection with novel MRI contrast agent

Onyvax raises funds to further its cancer vaccine programs

PDL demonstrates activity at low doses, safety of HuZAF in humans; plans trials in Crohn's disease

Preclinical profile of new Onyx-Bayer Ras pathway inhibitor described in detail at NCI-EORTC-AACR

First potent and selective MMP-13 inhibitor discovered using structure-based design

NPS-1407: a potent, orally active NMDA antagonist with neuroprotective, anticonvulsant properties

Preclinical evidence points to utility of FR-167653 in organ transplantation

Avigen and Bayer collaborate to bring Coagulin-B to market

Bradykinin antagonists and their use in the treatment of pain claimed in recent patent

New Na+/H+ exchange inhibitor protects against lung I/R injury in canine model

U.S. university researchers synthesize new heregulin antagonists based on rifamycin structure

Anticancer platinum complexes designed at Unitech

Novo Nordisk presents new series of PPAR-activating compounds for diabetes and obesity

New erythromycin-based antimicrobial agents identified at Pliva

Selective delta opioid receptor agonists in the SB pipeline

Merck's new integrin receptor antagonists for thrombosis, osteoporosis, atherosclerosis